News

Recent findings from a study published in JAMA Surgery reveal that gastric bypass surgery (RYGB) offers significant improvements in atherogenic blood lipids such as LDL cholesterol and apolipoprotein B (apoB), independent of weight loss and caloric restriction. This research challenges the conventional belief that these benefits are solely attributed to weight loss and calorie reduction.

Weight loss through bariatric surgery reduced the risk of major adverse cardiovascular events (MACE) by 42% and all-cause mortality by 37% in obese patients with moderate-to-severe obstructive sleep apnea (OSA) compared to those who did not undergo the surgery, according to the MOSAIC study. Dr. Ali Aminian from the Cleveland Clinic emphasized the study’s significance,

Preoperative use of GLP-1 drugs can significantly reduce complications for individuals with extreme obesity undergoing bariatric or metabolic surgery, according to a study presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting. These findings have not yet been published in a peer-reviewed journal. Extreme obesity, defined as a body

In a recent milestone, findings from the inaugural human trial of gastric mucosal ablation, a new minimally invasive weight loss procedure, were unveiled on Thursday. This non-surgical method demonstrated minimal side effects and boasted a brief outpatient recovery period compared to traditional weight loss interventions, albeit with slightly lesser weight reduction. Key Points: The study

In a significant development in obesity treatment research, a recent phase III randomized controlled trial (RCT) conducted by researchers from the Netherlands and published in The Lancet Regional Health – Europe has provided new insights into the long-term effects of two prevalent metabolic surgeries: sleeve gastrectomy and Roux-en-Y gastric bypass. Key Findings The study, known

Jayme Stokes of Wilmington Health recently accomplished the inaugural SADI-S procedure in the region, as announced by the practice. Stokes, a board-certified general and bariatric surgeon, executed a Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S). According to Stokes, “SADI-S marks a substantial leap forward in bariatric surgery, providing patients with a holistic approach to

Amid growing concerns regarding the expense associated with using glucagon-like peptide 1 agonists for obesity treatment, certain insurers are imposing additional restrictions or discontinuing coverage for these drugs altogether. Concurrently, there is a trend among healthcare plans to either maintain a certain level of accessibility to bariatric surgery or streamline the process for patients to